Pall Biotech

Scale-Up Right First Time With Allegro™ STR Bioreactors

Your cell culture solution from clinical to commercial scale

Download this poster to read how Celltheon successfully scaled their process from 3 L to 200 L, with reproducible product quality, productivity and cell growth profiles.


Download this poster A SMART platform for Scaleable Biotherapeutic Development: cDNA to 200L Single-use Stirred-tank Bioreactor to read how Celltheon successfully scaled their process from 3L to 200L, with reproducible product quality, productivity and cell growth profiles.

Fill out the form to download the poster and request a quote today!

Fill out the Form to Download the Poster

All fields required

Read what Divya Goel, VP of Business Development at Celltheon, has to say about the Allegro STR bioreactor


"The Allegro platform is an integrated, highly scalable manufacturing solution making process development and subsequent production more streamlined. By addressing previous limitations of key scalability parameters such as P/V, the time and resources spent on scale-up is reduced. Thus, the impact of this platform is reduction in timeline and COGS which directly benefits patients.”
 
"Many biosimilar developers are successful in developing a ‘bench-scale’ biosimilar but when they scale up, they lose productivity and/or quality preventing these programs from being commercially viable. The first generation of single-use bioreactors had certain limitations; the Allegro platform has addressed many of these concerns making it unique in replicating bench scale processes. It is truly a scalable platform."


Divya Goel, MBS
Vice President of Business Development
Celltheon Corporation

I was pleasantly surprised at the speed and quality of the process development work performed by Pall Biotech’s SLS and PDS teams. Both groups were proactive, transparent, and maintained a high level of communication. The outcome of using Pall’s Cadence BioSMB platform was the significant reduction of sorbent use per gram of material. These results were first simulated and subsequently confirmed using the bench scale continuous multi-column chromatography BioSMB platform.

Brad Sepp, Director, Manufacturing Sciences and Technology Manufacturing Operations